switching from glp 1 to tirzepatide between GLP‐1 receptor agonists in clinical practice: Expert consensus and practical guidance Switching from Semaglutide to Tirzepatide:

Users typically feel decreased appetite and cravings within a week or two, while body composition and metabolic improvements can be observed in 4-8 weeks with continued use

Summary available from: AAIC 2026 Li S, et al

SGLT2 inhibitors have shown cardiovascular benefits in patients with diabetes

What the FDA banned is the practice of making compounded versions of semaglutide unless it meets narrow, individualized medical criteria

Heres how it compares: Mechanism of Action: Unlike traditional diabetes medications such as metformin, which decreases glucose production in the liver, or insulin therapies that increase glucose uptake by the body's cells, empagliflozin works by blocking the reabsorption of glucose in the kidneys